Tris-(2,4-di-tert-butylphenyl) phosphite, also known as tris(2,4-di-tert-butylphenyl) phosphite, is a hindered phosphite ester. It is a versatile compound with applications in various fields, including polymer chemistry, catalysis, and as a stabilizer in organic materials. It is commonly used as a stabilizer in polymers to prevent oxidation and degradation, particularly in polyolefins. Its bulky tert-butyl groups provide steric hindrance, preventing the phosphite from reacting with free radicals that can lead to polymer degradation. The synthesis of tris-(2,4-di-tert-butylphenyl) phosphite typically involves the reaction of 2,4-di-tert-butylphenol with phosphorus trichloride. The hindered nature of the phosphite ester makes it a suitable ligand for transition metal catalysts, playing a role in various catalytic reactions. The compound has also been studied for its potential applications in the development of new flame retardants and antioxidants. Its unique properties, including its steric hindrance and its ability to scavenge free radicals, make it a promising candidate for these applications.'
tris-(2,4-di-tert-butylphenyl) phosphite: structure given in first source
ID Source | ID |
---|---|
PubMed CID | 91601 |
CHEBI ID | 144343 |
SCHEMBL ID | 26607 |
MeSH ID | M0222707 |
Synonym |
---|
AC-15273 |
tris(2,4-di-tert-butylphenyl) phosphite, 98% |
tris(2,4-ditert-butylphenyl) phosphite |
phenol, 2,4-di-tert-butyl-, phosphite (3:1) |
irgafos 168 |
einecs 250-709-6 |
phenol, 2,4-bis(1,1-dimethylethyl)-, phosphite (3:1) |
31570-04-4 |
tris(2,4-di-tert-butylphenyl) phosphite |
tris(2,4-di-tert-butylphenyl)phosphite |
AKOS001482440 |
FT-0655843 |
phosphorous acid tris(2,4-di-tert-butylphenyl) ester |
P1421 |
CHEBI:144343 |
tris(2,4-di-t-butylphenyl)phosphite |
tris(2,4-ditert-butylphenyl)phosphite |
A820911 |
phenol, 2,4-bis(1,1-dimethylethyl)-, 1,1',1''-phosphite |
unii-834e5h0lff |
834e5h0lff , |
tris-(2,4-di-tert-butylphenyl) phosphite |
ec 250-709-6 |
c42h63o3p |
tris-(2,4-di-tert-butylphenyl)phosphite |
BP-12274 |
irgafos-168 |
plastic additive 5 |
phosphite 168 |
jp-650 |
tris (2,4-di-tert-butyl-phenyl)phosphite |
everfos 168 |
2,4-bis(1,1-dimethylethyl)phenol phosphite (3:1) |
doverphos s 480 |
tris(2,4-tert-butylphenyl) phosphite |
plastic additive 5 [usp-rs] |
SCHEMBL26607 |
hostanox par 24 |
tris-(2,4-di-t-butylphenyl) phosphite |
lowinox 242 |
naugard 524 |
alkanox 240 |
tris (2,4-di-tert-butylphenyl) phosphite |
tris(2,4-di-tert butylphenyl)phosphite |
tris(2,4-di-tert.butylphenyl)phosphite |
antioxidant 168 , |
DTXSID2027969 |
sr-01000391442 |
SR-01000391442-1 |
mfcd00072706 |
plastic additive 5, united states pharmacopeia (usp) reference standard |
D70443 |
plastic additive 12, european pharmacopoeia (ep) reference standard |
tris(2,4-di-t-butylphenyl) phosphite |
tris(2,4-ditertbutylphenyl)phosphite |
tris(2,4-di-tert-butylphenyl)phosphite 100 microg/ml in acetonitrile |
AS-12273 |
as 2112; at 168; alkanox 240; alkanox p 240; antioxidant 168 |
Q27269395 |
CS-0035260 |
Class | Description |
---|---|
alkylbenzene | A monocyclic arene that is benzene substituted with one or more alkyl groups. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (13.33) | 18.2507 |
2000's | 5 (33.33) | 29.6817 |
2010's | 4 (26.67) | 24.3611 |
2020's | 4 (26.67) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (40.89) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (6.25%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 15 (93.75%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |